LGM Pharma

Ketoconazole

CAS No: 65277-42-1

Ketoconazole

LGM Pharma is a Ketoconazole 65277-42-1 active pharmaceutical ingredient supplier distributor, based in the USA.

Questions? Call our customer API support number 1-(800)-881-8210.

LGM Pharma offers this active ingredient but not the finished dosage forms.

Inquire about Ketoconazole

Product Details:

CAS No: 65277-42-1
AHFS Codes: 08:14.08 84:04.08.08
Synonyms:
  • 2%
  • Ketocanazole
  • Ketoconazol
  • Ketoconazol [INN-Spanish]
  • Ketoconazole [Usan:Ban:Inn:Jan]
  • Ketoconazolum [INN-Latin]
ATC code: D01AC08 G01AF11 J02AB02
Molecular Weight: 531.431 g/mol
PubChem: 47576
Chemical Formula: C9H7Cl2N5
DrugBank: DB01026 (APRD00401)
Assay/Purity: Typically NLT 98%
IUPAC Name: 1-[4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one
SMILES: CC(=O)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=CN=C3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
InChl: XMAYWYJOQHXEEK-UHFFFAOYSA-N

Additional Details: [+]

Indication: For the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis.
Pharmacodynamics: Ketoconazole, like clotrimazole, fluconazole, itraconazole, and miconazole, is an imidazole antifungal agent.
Mode of Action: Ketoconazole interacts with 14-_ demethylase, a cytochrome P-450 enzyme necessary for the conversion of lanosterol to ergosterol. This results in inhibition of ergosterol synthesis and increased fungal cellular permeability. Other mechanisms may involve the inhibition of endogenous respiration, interaction with membrane phospholipids, inhibition of yeast transformation to mycelial forms, inhibition of purine uptake, and impairment of triglyceride and/or phospholipid biosynthesis. Ketoconazole can also inhibit the synthesis of thromboxane and sterols such as aldosterone, cortisol, and testosterone.
Metabolism: Hepatic
Toxicity: Hepatotoxicity, LD50=86 mg/kg (orally in rat)
General Reference:
  1. Goeders NE, Peltier RL, Guerin GF: Ketoconazole reduces low dose cocaine self-administration in rats. Drug Alcohol Depend. 1998 Dec 1;53(1):67-77. Pubmed
  2. Berwaerts J, Verhelst J, Mahler C, Abs R: Cushingês syndrome in pregnancy treated by ketoconazole: case report and review of the literature. Gynecol Endocrinol. 1999 Jun;13(3):175-82. Pubmed
  3. Kazy Z, Puho E, Czeizel AE: Population-based case-control study of oral ketoconazole treatment for birth outcomes. Congenit Anom (Kyoto). 2005 Mar;45(1):5-8. Pubmed
  4. Pierard-Franchimont C, Goffin V, Decroix J, Pierard GE: A multicenter randomized trial of ketoconazole 2% and zinc pyrithione 1% shampoos in severe dandruff and seborrheic dermatitis. Skin Pharmacol Appl Skin Physiol. 2002 Nov-Dec;15(6):434-41. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1).
Any patent infringement and resulting liability is solely at buyer risk.